Laurion Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Laurion Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-30,860	Closed	-$3.37M	–	1262
2018 Q4	$3.37M	Buy	+30,860	New	+$3.86M	0.06%	363
2017 Q4	–	Sell	-111,807	Closed	-$5.07M	–	1815
2017 Q3	$5.07M	Buy	+111,807	New	+$4.47M	0.02%	505
2017 Q1	–	Sell	-11,000	Closed	-$302K	–	1548
2016 Q4	$302K	Buy	+11,000	New	+$442K	﹤0.01%	933
2014 Q3	–	Sell	-61,100	Closed	-$1.82M	–	388
2014 Q2	$1.82M	Buy	+61,100	New	+$1.93M	0.04%	199

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Laurion Capital Management's SRPT Position: Q1 2019 in Review

Laurion Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2019, closing a stake of 30,860 shares — an estimated $3.37M sold.

Laurion Capital Management first reported a position in SRPT in Q2 2014 and held it in 4 quarters. The position peaked at $5.07M in Q3 2017. 371 funds tracked by Wall St. Rank hold SRPT as of Q1 2019.

Laurion Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2019 after selling out during the quarter.
Laurion Capital Management sold 30,860 Sarepta Therapeutics shares in Q1 2019, an estimated $3.37M.
Laurion Capital Management first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 4 quarters.
Laurion Capital Management's Sarepta Therapeutics position peaked at $5.07M in Q3 2017.
371 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2019.

Based on Laurion Capital Management's 13F filing for Q1 2019, filed 8 May 2019.